Log in to search using one of your social media accounts:

 

Ipsen and Saol partner to co-promote Dysport in US
The US affiliate of French pharmaceutical company Ipsen has entered an exclusive, three-year agreement with Saol Therapeutics to promote Dysport (abobotulinumtoxinA) for approved therapeutic indications in adult spasticity and pediatric lower limb sp … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news

Dysport (Abobotulinumtoxin A Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 26, 2017 Category: Drugs & Pharmacology Source Type: news

Jailed Leawood businesswoman faces new charges
A Leawood woman in prison for tax evasion may have her stay extended. Kathleen Stegman, former owner of Midwest Medical Aesthetics Center Inc. in Leawood, was charged Friday with importing misbranded drugs. Prosecutors allege that Stegman obtained Botox, Dysport, Restylane, Perlane and Sculptra from foreign sources. In total, they claim she imported $194,000 of the drugs, which did not meet U.S. Food and Drug Administration labeling requirements. Stegman was sentenced in October to 51 months in… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 19, 2017 Category: Biotechnology Authors: Brian Kaberline Source Type: news

Jailed Leawood businesswoman faces new charges
A Leawood woman in prison for tax evasion may have her stay extended. Kathleen Stegman, former owner of Midwest Medical Aesthetics Center Inc. in Leawood, was charged Friday with importing misbranded drugs. Prosecutors allege that Stegman obtained Botox, Dysport, Restylane, Perlane and Sculptra from foreign sources. In total, they claim she imported $194,000 of the drugs, which did not meet U.S. Food and Drug Administration labeling requirements. Stegman was sentenced in October to 51 months in… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 19, 2017 Category: Health Management Authors: Brian Kaberline Source Type: news

Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
June 16, 2017 -- Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport (abobotulinumtoxinA) for injection for the treatment of spasticity in adults, based... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 16, 2017 Category: Drugs & Pharmacology Source Type: news

Everything You Ever Wanted To Know About Getting Botox In Your Groin
Most of us are familiar with botulinum toxin injections (commonly known by their brand names as Botox, Dysport and Xeomin) to erase facial wrinkles.  But Botox can also help people who suffer from excessive sweating, which is known as hyperhidrosis. In order to put a halt to sweating, it’s become increasingly more common to receive Botox injections in the armpits. And now, people are getting injections in their groin, as well.  HuffPost recently spoke with Dr. John H.Tu, M.D. from the University of Rochester Department of Dermatology and dermatologist for Dermatology Associates of Rochester. He fi...
Source: Healthy Living - The Huffington Post - June 5, 2017 Category: Consumer Health News Source Type: news

Grand jury indicts "fake doctor" of operating illegal Botox and laser clinics in Tempe, Scottsdale
A State Grand Jury indicted Craig Allen Scherf for allegedly operating illegal Botox and laser clinics in Tempe and Scottsdale. Scherf is not licensed by the Arizona Medical Board or any other agency governing the practice of medicine in Arizona, according to Arizona Attorney General Mark Brnovich. In January, investigators with the Arizona Attorney General's Office learned that Scherf was allegedly pretending to be a lic ensed doctor while providing Botox, Dysport and body laser treatments at a… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2017 Category: Biotechnology Authors: Angela Gonzales Source Type: news

Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients
Dysport (abobotulinumtoxinA) is an injectable formulation developed by Ipsen Biopharmaceuticals for the treatment of lower limb spasticity in paediatric patients aged two years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - August 25, 2016 Category: Pharmaceuticals Source Type: news

NeuroBreak: Alzheimer's $$; ALS Genes; Dysport for Kids
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 9, 2016 Category: Psychiatry Source Type: news

FDA Clears Dysport for Lower-Limb Spasticity in Kids FDA Clears Dysport for Lower-Limb Spasticity in Kids
Dysport is the first, and only, FDA-approved botulinum toxin for the treatment of pediatric lower-limb spasticity.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 3, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
BASKING RIDGE, N.J., Aug. 1, 2016 /PRNewswire/ -- Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2016 Category: Drugs & Pharmacology Source Type: news

Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
BASKING RIDGE, N.J., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved its ... Biopharmaceuticals, FDA Ipsen Biopharmaceuticals, Dysport, abobotulinumtoxin A, botulinum toxin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2016 Category: Pharmaceuticals Source Type: news

Ipsen Announces FDA Approval of Dysport(R) (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
PARIS--(Healthcare Sales & Marketing Network)--Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that the U.S. Food and Drug Administration (FDA) has approved Dysport® (abobotulinumtoxinA) for injection ... Biopharmaceuticals, FDA Ipsen, Dysport, abobotulinumtoxinA, lower limb spasticity (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2016 Category: Pharmaceuticals Source Type: news

Botox-Like Injection Might Ease Runners' Knee Pain
British researchers used Dysport to bring long-term relief for common ailment of physically active people (Source: WebMD Health)
Source: WebMD Health - February 22, 2016 Category: Consumer Health News Source Type: news

Botox-Like Injection Might Ease Runners' Knee Pain
British researchers used Dysport to bring long-term relief for common ailment of physically active people (Source: U.S. News - Health)
Source: U.S. News - Health - February 22, 2016 Category: Consumer Health News Source Type: news

Lavenburg Medical Group Announces Transition From Botox to Dysport for Skin Tightening and Anti-Wrinkle Treatments
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - October 4, 2015 Category: Pharmaceuticals Source Type: news

FDA accepts to review Ipsen's sBLA for Dysport to treat upper limb spasticity in adults
The US Food and Drug Administration (FDA) has accepted for review French pharmaceutical firm Ipsen's supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA) to treat upper limb spasticity in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - December 1, 2014 Category: Pharmaceuticals Source Type: news

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Ipsen and Galderma to expand their current distribution agreement for Dysport®/Azzalure® in aesthetic and dermatology indications to the US and Canada Ipsen and Galderma to collaborate on development and commercialization of new neurotoxins, inc... Biopharmaceuticals, Dermatology, DistributionIpsen, Galderma, Dysport, Azzalure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 11, 2014 Category: Pharmaceuticals Source Type: news

Ipsen Says Dysport Incontinence Treatment Trial PositiveIpsen Says Dysport Incontinence Treatment Trial Positive
French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2014 Category: Consumer Health News Tags: Urology News Source Type: news

France's Ipsen says Dysport incontinence treatment trial positive
PARIS (Reuters) - French drugmaker Ipsen said it had seen positive results from the first stage of a phase II trial of its Dysport brand in treating patients with a certain type of urinary incontinence. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become Profitable in the US in 2014
PARIS--(Healthcare Sales & Marketing Network)--Ipsen (Euronext: IPN; ADR: IPSEY) (IPN.PA) today announced that, as part of the accelerated execution of its strategy in the USA, the Group adopted a new organizational model for the distribution of Dysport&re... Biopharmaceuticals, NeurologyIpsen, Dysport (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2013 Category: Pharmaceuticals Source Type: news